Abiomed

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$38Mgeneral payments (2019-2025)
$212Kresearch payments (2019-2025)
52,098clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2019 $4.1M
2020 $2.4M
2021 $3.8M
2022 $5.7M
2023 $7.7M
2024 $8.9M
2025 $5.5M

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Interventional Cardiology $11M
Cardiovascular Disease $8.7M
Thoracic Surgery (Cardiothoracic Vascular Surgery) $6.0M
Advanced Heart Failure and Transplant Cardiology $2.2M
Critical Care Medicine (Internal Medicine) $1.2M
Anesthesiology $1.2M

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
George Vetrovec Richmond, VA Cardiovascular Disease $2,273,231.64
Navin Kapur Baltimore, MD Cardiovascular Disease $1,424,236.73
Amir Kaki Detroit, MI Interventional Cardiology $819,520.65
Rajiv Tayal Fredericksburg, VA Interventional Cardiology $554,619.06
Marc Dickstein New York, NY Anesthesiology $551,651.62
Scott Silvestry Orlando, FL Transplant Surgery $499,020.71
William Oneill Naples, FL Cardiovascular Disease $495,480.60
Daniel Raess Boxford, MA Thoracic Surgery (Cardiothoracic Vascular Surgery) $429,363.23
Rajan Patel New Orleans, LA Interventional Cardiology $424,160.83
Mark Anderson Philadelphia, PA Thoracic Surgery (Cardiothoracic Vascular Surgery) $413,421.30

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.